DGX vs. PNTG: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two stocks is more attractive to value investors?
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quest Diagnostics: Beat Down After Beating Q2 Estimates
Quest Diagnostics: Beat Down After Beating Q2 Estimates
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.
Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
On Tuesday, Quest Diagnostics Inc DGX posted second-quarter adjusted EPS of $2.35, beating the consensus of $2.34.
Quest Diagnostics Incorporated (DGX) Q2 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2024 Earnings Conference Call July 23, 2024 8:30 AM ET Company Participants Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Shawn Bevec - Vice President of Investor Relations Conference Call Participants Ann Hynes - Mizuho Securities Kevin Caliendo - UBS Michael Cherny - Leerink Patrick Donnelly - Citi David Westenberg - Piper Sandler Erin Wright - Morgan Stanley Brian Tanquilut - Jeffries Lisa Gill - JP Morgan Michael Ryskin - Bank of America Jack Meehan - Nephron Research Andrew Brackmann - William Blair Pito Chickering - Deutsche Bank Stephanie Davis - Barclays Operator Welcome to the Quest Diagnostics Second Quarter 2024 conference call. At the request of the company, this call is being recorded.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook
Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.
Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.31 per share. This compares to earnings of $2.30 per share a year ago.
Quest Diagnostics raises 2024 profit, revenue forecasts on health tests demand
Quest Diagnostics raised its 2024 profit and revenue forecasts on Tuesday, banking on robust demand for its health tests.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services
Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.
